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APOE-ε4 is best known as a risk factor for Alzheimer's disease (AD). Consequently, there is
considerable research interest in understanding whether APOE-ε4 influences cognition in
healthy adults. Despite a substantial literature reporting effects of APOE genotype on
cognition, findings are inconsistent. In particular, it is challenging to separate whether
cognitive deficits in APOE-ε4 carriers reflect the influence of prodromal dementia pa-
thology (“prodromal hypothesis”), or a direct contribution of APOE genotype to individual
differences (“phenotype hypothesis”). Variable methodology across studies further com-
plicates the issue. These challenges have limited what can be learnt about the processes
underlying cognitive ageing and dementia by studying the influence of APOE genotype on
cognition. In this review, we focus on the two compatible neurobiological mechanisms by
which APOE genotype may influence cognition in healthy adults (prodromal and pheno-
type). We summarise the behavioural evidence for the influence of APOE on cognition in
non-demented adults and explore key methodological challenges for disentangling the
cognitive effects of different neurobiological mechanisms of APOE. Evidence suggests that
at least some APOE-ε4 cognitive deficits are due to early AD pathology, whilst sensitive
measures of cognition are beginning to reveal subtle cognitive differences between APOE
genotypes in mid-adulthood, prior to the onset of the AD prodromal period. We concludeord Health Biomedical Research Centre, who had no role in writing the report or deciding to
uman Brain Activity, Warneford Hospital, Warneford Lane, Oxford, OX3 7JX, UK.
h.ox.ac.uk (M.C. O'Donoghue), susannah.murphy@psych.ox.ac.uk (S.E. Murphy), giovanna.
obre@psy.ox.ac.uk (A.C. Nobre), clare.mackay@ohba.ox.ac.uk (C.E. Mackay).
c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3104with recommendations for future research to investigate the cognitive consequences of
neurobiological processes affected by APOE and maximise the translational potential of
this research.
© 2018 Published by Elsevier Ltd.1. Introduction
Since the discovery of apolipoprotein-E (APOE) ε4 as a genetic
risk factor for Alzheimer's disease (AD; Corder et al., 1993;
Saunders et al., 1993), researchers have investigated whether
healthy ε4-carriers show impaired cognition or more rapid
cognitive decline compared to non-carriers, as an early sign of
impending dementia (e.g., Bondi et al., 1995; Staehelin, Perrig-
Chiello, Mitrache, Miserez, & Perrig, 1999; Wetter et al., 2005),
or source of variability in healthy cognitive ageing (e.g., Deary
et al., 2003, 2002; Greenwood & Parasuraman, 2003;
Greenwood, Lambert, Sunderland, & Parasuraman, 2005;
Helkala et al., 1996). Understanding the association between
APOE genotype and cognition in healthy adults can aid
development of preclinical biomarkers for AD, increase
knowledge of the mechanisms by which APOE-ε4 increases
AD risk, and inform interventions to boost cognition in older
adults. However, the reported effects of APOE on cognition are
highly inconsistent, and interpretation of these mixed find-
ings is complicated by conceptual and methodological
challenges.
A major challenge in understanding the association be-
tweenAPOE and cognition is the difficulty disentangling direct
influences of APOE genotype on a ‘cognitive phenotype’
(Greenwood& Parasuraman, 2003; Greenwood, Lambert, et al.,
2005) from the influence of greater prodromal AD pathology in
the at-risk group (Smith et al., 1998). In part, this stems from a
conceptual challenge where the two possibilities have been
framed as competing ‘hypotheses’ to explain the effect of
APOE on cognition (Bunce et al., 2014; Foster et al., 2013;
Greenwood & Parasuraman, 2003; Greenwood, Espeseth, Lin,
Reinvang, & Parasuraman, 2014; Greenwood, Sunderland,
Putnam, Levy, & Parasuraman, 2005; Hofer et al., 2002;
Negash et al., 2009; Parasuraman, Greenwood, & Sunderland,
2002), with evidence supporting one ‘hypothesis’ interpreted
as evidence against the other (e.g., Bondi, Salmon, Galasko,
Thomas, & Thal, 1999; Foster et al., 2013; Small, Basun, &
Backman, 1998; Smith et al., 1998). Unquestionably, the pro-
posed direct versus pathology-mediated cognitive effects
related to APOE genotype are underpinned by different
neurobiological mechanisms, but these need not be mutually
exclusive. Dissecting the relative influence of each neurobio-
logical mechanism on cognitive performance will ultimately
elucidate their roles in cognitive ageing and Alzheimer's
disease.
In this review, we outline two compatible neurobiological
mechanisms by which APOE genotype may influence cogni-
tion, and highlight the individual and interacting methodo-
logical challenges for separating the cognitive consequences
of eachmechanism. Themain objective is to demonstrate thatAPOE genotype may affect cognition via multiple neurobio-
logicalmechanisms, eachwith the potential to provide insight
into different aspects of cognitive ageing and Alzheimer's
disease. We conclude with recommendations for future
studies to facilitate interpretation of APOE-related effects and
increase the translational value of these findings.2. Neural mechanisms of APOE genotype
influence on cognition
The APOE gene has three major allelic variants e ε2, ε3 and ε4.
Individuals possess two APOE alleles, one inherited for each
parent, resulting in three homozygous genotypes e ε2ε2, ε3ε3,
ε4ε4 - and 3 heterozygous genotypese ε2ε3, ε2ε4, ε3ε4. APOE-ε3
is the most common allele, estimated to be present in 68e86%
of the Caucasian population, compared to 10e23% and 4e14%
for the ε4 and ε2 alleles, respectively (Davignon, Gregg, & Sing,
1988; Gerdes, Klausen, Sihm, & Faergeman, 1992; Myers et al.,
1996; Singh, Singh, & Mastana, 2006).
The APOE gene codes for the apolipoprotein-E lipid-trans-
port protein (ApoE). ApoE mediates the movement of choles-
terol between cells (Mahley, 1988), and provides essential
lipids for central nervous system (CNS) functions such as
neuronal growth, synaptic plasticity, and neuronal mainte-
nance and repair (Liu, Kanekiyo, Xu, & Bu, 2013). Structural
differences in ApoE proteins, which result from allelic varia-
tion in APOE genotype, are associated with isoform-specific
alterations of these CNS functions. For example, ApoE4 is
less efficient at transporting brain cholesterol compared to
ApoE3 (Rapp, Gmeiner, & Hu¨ttinger, 2006), which may disrupt
the supply of lipids needed for maintenance of synaptic
integrity and plasticity (Liu et al., 2013). Consistent with this,
animal models suggest APOE-ε4 genotype is associated with
delayed neuronal development (Nwabuisi-Heath, Rebeck,
Ladu, & Yu, 2014), lower dendritic spine density (Dumanis
et al., 2009), and reduced long-term potentiation (Trommer
et al., 2004), whilst human ε4-carriers show reduced synaptic
plasticity (Arendt et al., 1997), altered myelin formation (Dean
et al., 2014), and poorer outcomes following traumatic brain
injury (TBI; Zhou et al., 2008) and subarachnoid haemorrhage
(Martı´nez-Gonzalez & Sudlow, 2006; for a review of the role of
APOE genotype in a range of neurological disorders, see
Verghese, Castellano, & Holtzman, 2011).
The APOE-ε4 allele is the best known genetic risk factor for
sporadic Alzheimer's disease (Corder et al., 1993; Rocchi,
Pellegrini, Siciliano, & Murri, 2003). Carriers of the ε4 allele
show increased risk and earlier age of onset of AD, compared
to non-carriers (Borgaonkar et al., 1997; Corder et al., 1993;
Sando et al., 2008). ε4-related AD risk is conferred in a dose-
dependent manner, with greater risk and earlier age of onset
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et al., 1997; Liu et al., 2013). In contrast, possession of an ε2
allele may provide protection against AD diagnosis (for a re-
view of APOE-ε2, see Suri, Heise, Trachtenberg, & Mackay,
2013). The mechanisms by which APOE-ε4 increases AD risk
are not fully understood, but a role of ApoE4 in greater depo-
sition and/or reduced clearance of amyloid-b, resulting in
increased aggregation of this hallmark pathological feature of
AD, has been proposed (Huang, Weisgraber, Mucke, &Mahley,
2004). Isoform-specific effects on neuroinflammation, neuro-
genesis, and neuronal toxicitymay also contribute to increased
risk of AD in ε4-carriers (for a review of APOEmechanisms and
AD risk, see Liu et al., 2013). Possession of an APOE-ε4 allele is
neither necessary nor sufficient for development of AD
(Henderson et al., 1995; Hyman et al., 1996); however, approx-
imately half of ε4-homozygotes will develop AD by age 85,
compared to only 10% of non-carriers (Genin et al., 2011).
2.1. Prodrome
APOE genotype may influence cognition in currently healthy
adults indirectly via an increased presence of early AD pa-
thology in APOE-ε4 carriers. Whilst AD is typically diagnosed
after age 65 (McKhann, Drachman, Folstein,&Katzman, 1984),
the accumulation of pathology begins years prior to the onset
of clinical symptoms (Ohm, Mu¨ller, Braak, & Bohl, 1995;
Tondelli et al., 2012). Progressive cognitive impairment,
particularly in episodicmemory (Bondi et al., 2008;Weintraub,
Wicklund, & Salmon, 2012), is also detectable years before a
diagnosis is made (Amieva et al., 2005; Wilson, Leurgans,
Boyle, & Bennett, 2011). A proportion of any sample of
currently healthy older adults will be in the prodromal stage
that precedes clinical diagnosis of AD (Sliwinski, Lipton,
Buschke, & Stewart, 1996). The increased risk and earlier age
of onset of AD in APOE-ε4 carriers (Blacker et al., 1997; Corder
et al., 1993; Sando et al., 2008) means the proportion of pro-
dromal individuals will be greater in this at-risk group,
compared to non-carriers.
According to the ‘prodromal hypothesis’ (Foster et al., 2013;
Smith et al., 1998), cognitive deficits in healthy APOE-ε4 car-
riers, particularly in samples aged over 60 years, reflect the
indirect effect of prodromal AD pathology in a subset of ε4-
carriers who will go on to be diagnosed with AD. Some re-
searchers argue APOE genotype itself has no direct influence
on cognition, but rather observed ε4-related cognitive deficits
result entirely as a consequence of prodromal AD. In support
of this, a number of studies reported elimination of ε4-related
deficits after exclusion of incident AD cases (Bondi et al., 1999;
Hayden et al., 2009; Hofer et al., 2002; Knight et al., 2014;
Praetorius, Thorvaldsson, Hassing, & Johansson, 2013;
Winnock et al., 2002), and significantly faster cognitive
decline in ε4-carriers in domains affected in early AD (Bretsky,
Guralnik, Launer, Albert, & Seeman, 2003; Caselli, Dueck,
Locke, Hoffman-Snyder, et al., 2011; Haan, Shemanski, Jag-
ust, Manolio, & Kuller, 1999; Helkala et al., 1996; Hofer et al.,
2002; Hyman et al., 1996; Mayeux, Small, Tang, Tycko,& Stern,
2001; Packard et al., 2007; Riley et al., 2000; Schiepers et al.,
2012; Small et al., 1998; Yaffe, Cauley, Sands,& Browner, 1997),
as well as mediation of cognitive deficits in ε4-carriers by thepresence ofmild cognitive impairment (MCI) rather thanAPOE
genotype itself (Foster et al., 2013).
2.2. Phenotype
In contrast to a strong prodromal view, other researchers
consider that APOE genotype may exert a direct effect on
cognition, independent of future AD diagnosis, via genotype-
specific influences on neurobiological processes that affect
cognition (Greenwood & Parasuraman, 2003; Parasuraman &
Greenwood, 2004). Genetics are an important determinant of
cognitive ability (Plomin, DeFries, McClearn, & McGuffin,
2001), and normal allelic variation may contribute to individ-
ual differences in cognitive abilities throughout life. This
cognitive neurogenetic approach (Greenwood & Parasuraman,
2003; Parasuraman & Greenwood, 2004) proposes a cascade
of events linking genotype to cognitive phenotype (also see
Deary, Penke, & Johnson, 2010; Meyer-Lindenberg & Wein-
berger, 2006; Reinvang, Deary, et al., 2010). As the isoform
structure of a protein depends on the specific genotype of the
coding gene, this will result in isoform-specific alteration of
neurobiological endophenotypes, ultimately producing variable
cognitive phenotypes.
According to the ‘phenotype hypothesis’ (Greenwood &
Parasuraman, 2003; Greenwood, Lambert, et al., 2005;
Parasuraman et al., 2002), the putative roles of ApoE in CNS
functions, such as synaptic plasticity and repair, provide an
altered neural endophenotype by which APOE genotype may
result in a ‘cognitive phenotype’. According to this hypothesis,
cognitive differences in ε4-carriers are not confined to older
adults and are independent of subsequent AD diagnosis
(Greenwood, Lambert, et al., 2005). Neuroimaging studies in
younger adults (under 60 years) provide corroborative results
that suggest APOE-ε4 is associated with differences in the
brain prior to the onset of AD pathology, in a manner inde-
pendent of future AD. Similar patterns have been observed in
at-risk ε4-carriers and low-risk ε2-carriers, compared to ε3-
carriers, in task and resting-state functional MRI, as well as
white matter (WM) integrity (e.g., Trachtenberg, Filippini,
Cheeseman, et al., 2012; Trachtenberg, Filippini, Ebmeier,
et al., 2012; Westlye, Reinvang, Rootwelt, & Espeseth, 2012;
for reviews of APOE genotype effects on MRI measures in
healthy adults, see Fouquet, Besson, Gonneaud, La Joie, &
Chetelat, 2014; Trachtenberg, Filippini, & Mackay, 2012).
Whilst the association between APOE and Alzheimer's
disease is unusually strong for an individual susceptibility
geneedisease association (Genin et al., 2011), a direct effect of
APOE on a cognitive phenotype is likely to be subtle. Cognitive
ability is influenced bymultiple genes, environmental factors,
and complex geneeenvironment interactions, so any single
gene will exert only a small effect on a cognitive phenotype
(Marian, 2012). However, the phenotypic influence of APOE on
cognition may be particularly observable in later life. The in-
fluence of genetics on cognition is thought to increase with
age (e.g., McClearn et al., 1997; McGue & Christensen, 2002),
possibly due to neuronal and neurochemical losses with age
that highlight genetic influences on cognition (Lindenberger
et al., 2008). Normal allelic variation may therefore partic-
ularly contribute to increased variability in cognitive
c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3106performance in older adults (e.g., Christensen et al., 1999;
Wilson, Beckett, et al., 2002).3. Literature search
For this comprehensive review of APOE and cognition studies
in healthy adults, online searches were performed in PubMed
using combinations of the following search terms: ‘APOE’,
‘apolipoprotein’, ‘cognition’, ‘cognitive’, ‘performance’,
‘cognitive ability’, and ‘cognitive abilities’. Only studies pub-
lished from 1993, when APOE genotype was identified as a risk
factor for AD (Corder et al., 1993), were considered.
Studies that used neuropsychological measures, forming
the majority of the literature, were considered for inclusion in
Tables 1 and 2. Participants were required to be cognitively
healthy and grouped by APOE genotype. Any studies that
included individuals with objective cognitive impairment or
clinical diagnoses at baseline were not included, unless re-
sults were separately reported for non-demented partici-
pants. Studies with highly selected samples, e.g., women on
hormone replacement therapy, were also not included.
Studies that focused on APOE genotype interactions with
other variables, includingMRImetrics, were not included. Age
of the sample (range or mean) and follow-up duration, where
applicable, were required to be reported for inclusion. Only
studies published in English were considered. As detailed
discussion of neuroimaging findings is beyond the scope of
this review, functional MRI studies were not included and are
reviewed elsewhere (see Trachtenberg et al., 2012). Studies
with overlapping samples were not excluded (e.g., Bunce,
Anstey, Burns, Christensen, & Easteal, 2011; Jorm et al., 2007).4. Summary of research findings
In the last twenty years, many studies have investigated the
influence of APOE genotype on cognition in the absence of
diagnosed dementia. A large proportion of these studies
compared the performance of older adults on neuropsycho-
logical tests between APOE-ε4 carriers and non-carriers,
particularly on measures of episodic memory (Small,
Rosnick, Fratiglioni, & B€ackman, 2004; Wisdom, Callahan, &
Hawkins, 2011). The effect of APOE on cognition has also
been investigated across the lifespan, from children to the
oldest-old, using cross-sectional and longitudinal cognitive
measures spanning a range of cognitive domains, including
semantic memory, working memory, executive function,
processing speed, attention, visuospatial processing, lan-
guage, intelligence, and tests of global cognition, as well as a
smaller selection of experimental cognitive tasks.
Despite this breadth of investigation, a consistent pattern
of results has failed to emerge. Whilst many cross-sectional
studies have reported significant cognitive deficits in APOE-
ε4 carriers compared to non-carriers across a range of cogni-
tive domains (Bondi et al., 1995; Bondi et al., 1999; Caselli et al.,
2001; Chey, Kim, & Cho, 2000; Deary et al., 2004, 2002; Flory,
Manuck, Ferrell, Ryan, & Muldoon, 2000; Houston et al., 2005;
Izaks et al., 2011; Jacobson, Delis, Lansing, et al., 2005;
Jacobson, Delis, Bondi, & Salmon, 2005; Laukka et al., 2013;Levy et al., 2004; Liu et al., 2010; Luciano, Gow, Harris, et al.,
2009; Luck et al., 2015; Nao et al., 2017; O'Hara et al., 2008;
Reed et al., 1994; Rosen, Bergeson, Putnam, Harwell, &
Sunderland, 2002; Rosen et al., 2005; Sager, Hermann, & La
Rue, 2005; Schmidt et al., 1996; Schultz et al., 2008; Striepens
et al., 2011; Welsh-Bohmer et al., 2009; Wetter et al., 2005),
other studies have found no significant effect of APOE geno-
type on cognition (Bathum et al., 2006; Berteau-Pavy, Park, &
Raber, 2007; Bunce et al., 2011; Caselli et al., 1999; Caselli et al.,
2002; Chen et al., 2002; Driscoll, McDaniel, & Guynn, 2005;
Duchek, Balota, & Cortese, 2006; Foster et al., 2013; Green-
wood, Sunderland, Friz, & Parasuraman, 2000; Jorm et al.,
2007; Kim et al., 2002; Liu et al., 2010; Luciano, Gow, Taylor,
et al., 2009; Payton et al., 2006; Quintas et al., 2014; Reiman
et al., 1996; Richter-Schmidinger et al., 2011; Salo et al., 2001;
Small et al., 2000; Ward et al., 2014; Wetter et al., 2006; Ystad
et al., 2009; Zhang, Ren, et al., 2015; Zhang, Chen, et al., 2015).
Table 1 summarises the reported effects of APOE on cross-
sectional neuropsychological measures of cognition,
including the cognitive domains tested in each case (definition
of cognitive domains is detailed in the Supplementary Table).
A small number of studies reported superior performance in
ε4-carriers, although such findings are typically restricted to
young (e.g., under 30 years; Mondadori et al., 2007; Schultz
et al., 2008) or very old (e.g., over 80 years; Carrion-Baralt
et al., 2009; Smith et al., 1998) samples.
Table 2 summarises the reported APOE effects from lon-
gitudinal studies, including sample age at baseline, length of
follow-up period, and screening at baseline and follow-up(s).
Many such studies have reported more rapid cognitive
decline in APOE-ε4 carriers (Andrews, Das, Cherbuin, Anstey,
& Easteal, 2016; Baxter, Caselli, Johnson, Reiman, & Osborne,
2003; Bretsky et al., 2003; Carmelli et al., 2000; Caselli et al.,
2004; Caselli et al., 2009; Caselli, Dueck, Locke, Hoffman-
Snyder, et al., 2011; Christensen et al., 2008; Donix et al.,
2012; Greenwood et al., 2014; Helkala et al., 1996; Hofer et al.,
2002; Jochemsen,Muller, Graaf,&Geerlings, 2012; Jonker et al.,
1998; Mayeux et al., 2001; Praetorius et al., 2013; Riley et al.,
2000; Schiepers et al., 2012; Shadlen et al., 2005; Small et al.,
1998; Tupler et al., 2007; Wilson, Bienias, Berry-Kravis, Evans,
& Bennett, 2002), with some also reporting baseline ε4-related
deficits (Barnes et al., 2013; Blair et al., 2005; Lavretsky et al.,
2003; Packard et al., 2007; Sapkota, B€ackman, & Dixon, 2017;
Yaffe et al., 1997; Zehnder et al., 2009). However, other longi-
tudinal studies observed no difference in rate of cognitive
decline between APOE genotype groups (Batterham, Bunce,
Cherbuin, & Christensen, 2013; Bunce, Fratiglioni, Small,
Winblad, & B€ackman, 2004; Bunce et al., 2014; Cohen, Small,
Lalonde, Friz, & Sunderland, 2001; Deary et al., 2003; Dik
et al., 2000; Jarvik et al., 2005; Juva et al., 2000a; Knight et al.,
2014; Mortensen & Høgh, 2001).
As illustrated in Tables 1 and 2, many studies have
investigated the effect of APOE genotype on not only one
cognitive test, but on extensive cognitive batteries assessing
multiple cognitive domains in the same sample (e.g., Caselli
et al., 2001; Duchek et al., 2006; Foster et al., 2013; Levy
et al., 2004). In these studies, ε4-related deficits have often
been reported in some, but not all, domains, suggesting a
domain-specific effect of APOE-ε4 on cognition, with episodic
memory particularly affected. However, the pattern of spared
Table 1 e Cross-sectional neuropsychological performance by domain, ordered by mean age of sample.
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c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3108versus impaired performance across cognitive domains is
inconsistent across studies. Whilst many studies have re-
ported an ε4-related deficit in at least one cognitive domain,
the majority of comparisons have resulted in non-significant
effects (see Tables 1 and 2). Meta-analyses addressing the
domain specificity of APOE effects on cognition, primarily inolder samples (over 60 years), suggest APOE-ε4 carriers are
specifically impaired on measures of episodic memory, ex-
ecutive function, global cognition, and possibly perceptual
speed, but there is no genotype effect on verbal ability,
attention, visuospatial function, and primary memory (Small
et al., 2004; Wisdom et al., 2011).
Table 2 e Longitudinal neuropsychological performance by domain, ordered by screening method.
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c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3110Interpretation of these heterogeneous findings is chal-
lenging. Methodological factors such as age of sample,
sample size, and cognitive measures vary substantially
among studies, making cross-study comparisons difficult.
Inconsistent reporting of the substantial number of potential
modifying variables limits the value of meta-analysis to shed
light on the sources of heterogeneity in this literature (Small
et al., 2004; Wisdom et al., 2011). Additionally, since the
majority of research in this field is conducted in older sam-
ples, it is often unclear whether observed ε4-deficits relate to
a direct effect of APOE on cognition or the presence of pro-
dromal AD. In many cases, it is also difficult to resolve
whether the absence of significant APOE effects on cognition
reflects a genuine lack of genetic effect, or rather a lack of
statistical power or insensitive cognitive measures. For
example, several studies that reported null effects had large
samples (N > 1000) and therefore high statistical power
(Bathum et al., 2006; Bunce et al., 2011; Jorm et al., 2007; Liu
et al., 2010; Luciano, Gow, Taylor, et al., 2009), but some
had young and mid-adulthood samples, so the cognitive
measures used may not have been sensitive to an APOEeffect in this age group (see 5. Methodological challenges for
further discussion). Other studies with similarly large sam-
ples, all with older adults, observed significant cognitive
deficits in ε4-carriers (Izaks et al., 2011; Laukka et al., 2013;
Liu et al., 2010; Luciano, Gow, Harris, et al., 2009).
Disentangling the cognitive consequences of the neurobi-
ological mechanisms by which APOE may influence cognition
requires methodology that is optimised to addresses specific
research questions. Multiple methodological factors must be
optimised in concert to improve the ability to interpret find-
ings. Consideration of ‘prodromal’ and ‘phenotypic’ as
distinct but compatible neurobiological mechanisms, rather
than competing hypotheses, will aid the separation of direct
and prodromal effects of APOE on cognition. Fig. 1 highlights
the importance of separating these cognitive effects of APOE,
as they can provide insight into separate neurobiological
processes, with applications to distinct aspects of cognitive
ageing and Alzheimer's disease. In the next sections, we
highlight key methodological challenges for investigating the
cognitive effects of different underlying neurobiology of APOE,
and make recommendations for future studies.
Fig. 1 e An overview of the possible phenotype and prodrome effects of APOE on cognition, and potential insights to be
gained from increased understanding of each mechanism.
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5.1. Age
Age is a major methodological challenge for separating direct
effects of APOE on cognition from the cognitive consequence
of early AD pathology, as sample age determines the mecha-
nism that can be studied. The long prodromal period of AD
makes it difficult to rule out the influence of AD pathology in
elderly samples, particularly given the earlier age of AD onset
in APOE-ε4 carriers. Significant interactions between age and
APOE genotype in older samples (over 60 years), representingan increasing negative influence of APOE-ε4 genotype on
cognition with age (e.g., Baxter et al., 2003; Caselli et al., 1999;
Laukka et al., 2013; Wisdom et al., 2011), may reflect an
increasing presence of AD pathology with age, although other
studies have found no significant interaction of age and ge-
notype (Bunce et al., 2011, 2014; Jorm et al., 2007; Small et al.,
2000, 2004). Cross-sectional findings in Table 1 are ranked by
mean age of sample, but a clear pattern does not emerge.
Variable and often broad age ranges between studies make
comparison of findings challenging.
To minimise inclusion of prodromal AD, most studies use
cognitive screening in older samples. However, themethod of
c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3112cognitive screening used varies greatly between studies (see
Table 2), including a single clinician or consensus panel de-
cision, use of clinical diagnostic tools such as the Cambridge
Mental Disorders of the Elderly Examination (CAMDEX; Roth
et al., 1986) or the Clinical Dementia Rating tool (CDR;
Morris, 1993), and varying thresholds of theMini-Mental State
Examination (MMSE; Folstein, Folstein, & McHugh, 1975),
whilst other studies report no details of the cognitive
screening used, if any. A stringent cognitive screening
approach used in a small number of studies is retrospective
exclusion of individuals diagnosed with AD during a follow-
up period from the cross-sectional analysis of baseline data.
Studies using this approach found significant baseline ε4-
related deficits in episodic memory, executive function,
attention, semantic memory, processing speed, language,
and global cognition were no longer significant after incident
AD cases were excluded (Bondi et al., 1999; Hayden et al.,
2009; Hofer et al., 2002; Knight et al., 2014; Laukka et al.,
2013; Praetorius et al., 2013; also see Batterham et al., 2013;
Jorm et al., 2007; Schiepers et al., 2012), suggesting the
initial ε4-deficits were due to prodromal AD (also see 5.3.
Sample size and longitudinal design). However, in some studies,
significant ε4-deficits in memory, perceptual speed, and
global cognition remained after exclusion of incident AD
cases (Hofer et al., 2002; Jonker et al., 1998; Laukka et al., 2013;
Praetorius et al., 2013; Winnock et al., 2002; also see B€ackman
et al., 2004; Riley et al., 2000). Even with stringent methods,
the possible influence of prodromal AD in older samples is
difficult to rule out.
Several observations indicate that the association between
APOE genotype and cognition also changes across the life-
span. Children and young adults (under 30 years) who possess
an APOE-ε4 allele have demonstrated superior cognitive per-
formance (e.g., Bloss, Delis, Salmon,& Bondi, 2010; Mondadori
et al., 2007; Schultz et al., 2008; Wright et al., 2003; although
see Bunce et al., 2011, 2014; Ihle, Bunce, & Kliegel, 2012). This
effect is proposed to reflect ‘antagonistic pleiotropy', where
the influence of a gene changes across the lifespan, being
evolutionarily advantageous in early life, but exerting a
negative effect later in life (Han & Bondi, 2008; Tuminello &
Han, 2011; Williams, 1957). Some researchers have argued
that ApoE4 has a possible protective role in development (e.g.,
Alexander et al., 2007), but this is controversial (e.g., Dumanis
et al., 2009; Klein, Mace, Moore, & Sullivan, 2010; Shaw et al.,
2007). Furthermore, a meta-analysis found no evidence for
an APOE-ε4 related cognitive benefit in young people (Ihle
et al., 2012).
At the other end of the lifespan, superior cognitive per-
formance has been reported in the oldest ε4-carriers (over 80
years), compared to non-carriers (Carrion-Baralt et al., 2009;
Duchek et al., 2006), as well as attenuation of ε4-deficits
observed in young-old carriers (Negash et al., 2009; Riley
et al., 2000; Smith et al., 1998). These cognitive effects corre-
spond with reported attenuation of the association between
APOE-ε4 and Alzheimer's disease risk in the oldest-old
(Blacker et al., 1997; Breitner et al., 1999; Corrada, Paganini-
Hill, Berlau, & Kawas, 2013; Farrer et al., 1997; Juva et al.,
2000a; Valerio et al., 2014; also see Kozauer, Mielke, Chan,
Rebok, & Lyketsos, 2008). The oldest-old non-demented
APOE-ε4 carriers have been proposed to represent ‘selectivesurvivors’ (Duchek et al., 2006), resilient to the negative in-
fluences of APOE-ε4 on development of AD (Rebeck et al., 1994)
or cardiovascular disease (Stenga˚rd, Pekkanen, Ehnholm,
Nissinen, & Sing, 1996) earlier in life. This may reflect the in-
fluence of additional protective factors (Carrion-Baralt et al.,
2009) or absence of other AD risk factors (Tuminello & Han,
2011). However, the attenuation of associations between
APOE-ε4 and cognition or AD risk in the oldest-old has not
been consistently reported (Gebner, Reischies, Kage,
Geiselmann, & Borchelt, 1997; Nilsson et al., 2006; Rebeck
et al., 1994), and some studies have found no APOE effects
(Bathum et al., 2006; Berteau-Pavy et al., 2007; Juva et al.,
2000b; Riley et al., 2000; Salo et al., 2001; Small et al., 1998) or
ε4-related cognitive deficits in the oldest-old (Praetorius et al.,
2013; Riley et al., 2000; Small et al., 1998; Welsh-Bohmer et al.,
2009).
To investigate genetic effects in the absence of prodromal
AD pathology, studies have more recently moved to investi-
gate the effect of APOE on cognition in mid-adulthood (30e60
years) samples, before AD pathology is likely to accumulate.
Possible antagonistic pleiotropic effects in early life may also
be avoided in mid-adulthood samples. Due to the long period
of accumulation of AD pathology before symptom onset, in-
dividuals in their late 50s may already fall into the prodromal
AD pre-dementia stage, meaning that a more restricted age
range (e.g., 30e50 years) may be optimal. Without very large
samples, the inclusion of participants with a wide age range
(Caselli, Dueck, Locke, Hoffman-Snyder, et al., 2011; Wishart
et al., 2006) is unlikely to provide clear results.
5.2. Cognitive measures
Cognitive measures are key to unpicking the cognitive effects
of the prodromal and direct neurobiological mechanisms of
APOE. The neuropsychological measures used in most
studies, whilst well-validated and quick to administer, typi-
cally lack the sensitivity to detect subtle variation in cognition
(Houx et al., 2002; Jorm et al., 2007) and lack the specificity to
measure variation in isolated cognitive processes (Greenwood
et al., 2000, Greenwood, Lambert, et al., 2005; Wisdom et al.,
2011). Neuropsychological tests therefore have limited use
for investigating the direct effect of APOE on a cognitive
phenotype in mid-adulthood samples, and a recent meta-
analysis found no evidence for an APOE genotype effect on
midlife neuropsychological performance (Lancaster, Tabet, &
Rusted, 2017).
More sensitive ‘cognitive assays’ that target specific
cognitive processes are required to detect subtle direct
cognitive effects of APOE genotype (Greenwood, Lambert,
et al., 2005). Several studies in older adults have reported se-
lective ε4-related deficits on sensitive cognitive neuroscience-
based measures of prospective memory, implicit learning,
spatial navigation and working memory (Berteau-Pavy et al.,
2007; Driscoll et al., 2005; Duchek et al., 2006; Negash et al.,
2007; Reinvang, Winjevoll, Rootwelt, & Espeseth, 2010; Rosen
et al., 2002). However, in older samples, such sensitive mea-
sures again face the challenge of isolating direct effects of
APOE from the potential influence of incipient AD. In a study
by Negash et al., 2007, older APOE-ε4 carriers demonstrated
deficits in contextual cueing, but no APOE-related effect on
c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3 113serial reaction time performancewas observed, interpreted as
a selective effect of APOE-ε4 on medial temporal function, but
spared frontal function. However, the same pattern of spared
and impaired performance was also observed using the same
measures in a sample diagnosed with MCI, regardless of APOE
status (Negash et al., 2007).
Sensitive cognitive measures have only been used in a
small number of studies to investigate APOE-related effects in
mid-adulthood samples, although this number is increasing.
Many such studies come from Greenwood and colleagues,
who, based on observed cognitive deficits in AD patients
(Parasuraman et al., 2002), have investigated whether ε4-
carriers show selective deficits in attentional processes in
mid-adulthood. In a series of experiments, mid-adulthood
APOE-ε4 carriers demonstrated intact sustained attention,
but impaired attentional disengagement in a cued discrimi-
nation task, and impaired scaling of attention during a visual
search task (Espeseth et al., 2006; Greenwood, Lambert, et al.,
2005, Greenwood, Sunderland, et al., 2005, Greenwood et al.,
2000; Negash et al., 2009; although see Lancaster, Forster,
Tabet, & Rusted, 2017). Longitudinally, APOE-ε4 homozygotes
showed increasingly impaired attentional scaling during vi-
sual search, whilst non-carriers improved over 3 years
(Greenwood, Sunderland, et al., 2005). Additionally, mid-
adulthood ε4-carriers showed cross-sectional selective defi-
cits in retaining visuospatial information in working memory
(Greenwood, Lambert, et al., 2005; although see Greenwood
et al., 2014). Surprisingly, Greenwood et al., 2014 reported a
significant improvement in working memory performance in
mid-adulthood ε4-carriers when retested after 3 years, whilst
non-carriers showed longitudinal decreases in performance,
interpreted by the authors as possible cognitive compensation
in APOE-ε4 carriers.
More recently, other researchers have expanded the
investigation of APOE effects on mid-adulthood cognition to
other cognitive domains. A study by Salvato, Patai, McCloud,&
Nobre, 2016 investigated the effect of APOE genotype on long-
term memory-guided attention in a mid-adulthood sample
(mean age 45.7 years). Whilst APOE genotype had no signifi-
cant effect on explicit memory or memory-guided attention,
ε4-homozygotes showed an impaired correlation between
memory and attention, indicating the memories guiding
attentional orienting in ε4-homozygotes were not explicitly
available (Salvato et al., 2016). The authors suggested these
cognitive results might reflect changes in brain regions that
underpin long-term memory-guided attention, e.g., medial
temporal, parietal and frontal regions, which are also
compromised in AD (Salvato et al., 2016). In another study,
adults aged 40e51 completed a short-termmemory paradigm
where participants were required to hold multiple fractals in
memory, and after a short delay identify which of 2 fractals
had previously been presented, as well as the location in
which it was shown (Zokaei et al., 2017). This task was pre-
viously shown to be sensitive to memory deficits in patients
with medial temporal lobe (MTL) damage (Pertzov et al., 2013).
Intriguingly, this paradigm revealed a behavioural advantage
in male APOE-ε4 carriers, with less mislocalisation of the
remembered item to the location of another item held in
memory, interpreted as a possible example of antagonistic
pleiotropy in midlife (Zokaei et al., 2017).The breadth of domains studied with sensitive cognitive
assays remains relatively limited to those impaired in patients
with AD/MTL damage. Investigation of further neuro-
biologically relevant domains is warranted. To robustly
investigate the direct effect of a gene on behaviour, the
measured phenotype should reflect the likely altered neuro-
biological endophenotype, to provide a plausible and mecha-
nistic association between genotype and phenotype (Goldberg
& Weinberger, 2004). Additional cognitive processes that are
biologically related to the proposed influence of APOE geno-
type on CNS function, e.g., synaptic plasticity and neuronal
repair (Liu et al., 2013), should therefore be explored. Tasks
that assess long-term learningmay be particularly sensitive to
such effects of APOE genotype on CNS functions (see 6.1.
Recommendations for phenotype effect of APOE on cognition).
Characterisation of the APOE-ε4 cognitive effects related to
prodromal ADmay also benefit from amore selective focus on
measures relevant to the underlying neurobiology. Numerous
studies have assessed the effect of APOE genotype on exten-
sive neuropsychological batteries, regardless of the associa-
tion of each measure with cognitive impairments in early AD.
The resulting multiple comparisons problem is inconsistently
and sometimes insufficiently controlled for. A more selective
assessment of cognitive domains may be advantageous, for
example those recommended in a recent consensus state-
ment on cognitive outcomes in preclinical AD based on
cognitive correlates of preclinical brain changes, including
verbal episodic memory, working memory, and navigation in
egocentric space (Ritchie et al., 2017).
5.3. Sample size and longitudinal design
The lower frequency of APOE-ε4 in the population, compared
to APOE-ε3, has resulted in consistently smaller APOE-ε4
samples in most studies, unless specifically matched between
groups (e.g., Caselli et al., 2001, 1999; Salvato et al., 2016;
Zokaei et al., 2017). There are also relatively few in-
vestigations of the specific effect of APOE-ε2 on cognition, due
to the low occurrence of the ε2 allele in the population
(although see Bartres-Faz et al., 1999; Batterham et al., 2013;
Blair et al., 2005; Bloss et al., 2010; Bunce et al., 2014; Chey
et al., 2000; Chiang, Raptentsetsang, & Jack, 2010; Greenwood
et al., 2000; Helkala et al., 1995, 1996; Hofer et al., 2002;
Marioni et al., 2016; Pendleton et al., 2002; Quintas et al.,
2014; Salo et al., 2001; Staehelin et al., 1999; Ward et al.,
2014; Wilson, Bienias, et al., 2002; Lancaster, Forster, et al.,
2017). Table 1 also illustrates the variability in sample size
across studies.
The required sample size may depend on the neurobio-
logical mechanism of APOE under investigation. Longitudinal
studies are required to investigate prodromal APOE-ε4 cogni-
tive effects in relation to clinical outcomes, e.g., for biomarker
development. Therefore, a large initial sample is required, as
cognitive effects will be driven by only a subsample with early
AD, and some participants may be lost to follow-up. Sufficient
sample size is particularly important if incident AD cases will
be retrospectively excluded from baseline analysis, as these
cases are more likely to be excluded from the already smaller
APOE-ε4 group (e.g., Batterham et al., 2013). Elimination of
initially significant baseline APOE effects after exclusion of
c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3114incident AD (e.g., Bondi et al., 1999; Hayden et al., 2009; Hofer
et al., 2002; Knight et al., 2014; Praetorius et al., 2013) may have
resulted from degraded statistical power in some cases. In
contrast, a subtle APOE-related cognitive phenotype should be
present in all ε4-carriers, therefore smaller samples may be
sufficient, as long as the cognitive measures used test appro-
priate domains and are sufficiently sensitive.6. Recommendations for future research
In the previous sections, we have outlined the mixed reported
effects of APOE on cognition, and discussed how key meth-
odological factors complicate the interpretation of these
findings. Some studies have attempted to facilitate interpre-
tation by addressing individual methodological challenges
(e.g., larger sample size or under-studied cognitive domain).
However, the interactive nature of these methodological fac-
tors requires multiple aspects of methodology to be optimised
simultaneously to aid the interpretation of APOE and cogni-
tion results. Future studies can add to our understanding of
the prodromal and direct routes of APOE influence on cogni-
tion by employing methodology targeted at specific neurobi-
ological mechanisms, to simplify the interpretation of results.
Here we make recommendations for future studies (sum-
marised in Fig. 1).
6.1. Recommendations for phenotype effect of APOE on
cognition
As evidence for APOE-related alterations of CNS functions
has primarily come from animal literature, evidence of an
APOE cognitive phenotype would provide support for an
altered neural endophenotype in humans. The applications
of this knowledge are two-fold: firstly, to provide greater
understanding of the neurobiological processes altered by
APOE genotype, and secondly, to inform how genetic vari-
ability contributes to individual differences in cognition,
providing targets for interventions to maximise cognition in
non-neuropathological ageing. The amyloid-independent
mechanism(s) that directly influence cognition in ε4-carriers
may also reflect a ‘susceptibility’ factor that contributes to
increased risk of AD (Greenwood, Lambert, et al., 2005), and
may interact with amyloid-dependent pathways by promot-
ing amyloid deposition (Verghese et al., 2011), or exacerbating
the impact of amyloid deposition, possibly via proin-
flammatory responses (Liu et al., 2013). Greater understand-
ing of the direct effect of APOE genotype on a cognitive
phenotype may therefore inform interventions to ameliorate
increased risk of AD in ε4-carriers.
Whilst future studiesmay avoid the influence of prodromal
AD when investigating an APOE cognitive phenotype by
excluding volunteers positive for preclinical AD biomarkers,
e.g., increased amyloid or reduced glucosemetabolism on PET
imaging, or reduced CSF amyloid (Sperling et al., 2011), limited
resources and invasiveness of procedures means such
screening is not always feasible. Instead, the use of mid-
adulthood samples (30e50 years) is optimal to investigate a
cognitive phenotype prior to the development of AD pathol-
ogy, whilst also avoiding possible antagonistic pleiotropiceffects of APOE on cognition earlier in life. Future research
should also examine cognitive domains relevant to the puta-
tive neurobiological mechanisms affected by APOE-ε4 using
sensitive and specific cognitive measures. A promising initial
target is the effect of APOE genotype on long-term learning
over days or weeks, e.g., learning a new skill (Scholz, Klein,
Behrens, & Johansen-Berg, 2009), rather than minutes or
hours tested in neuropsychological assessments, to reflect the
effect of disrupted lipid provision on synaptic plasticity.
Alternatively, the detrimental effect of APOE-ε4 on response to
neuronal injury, via neuronal repair, neuroinflammatory, or
neurotoxicity mechanisms (Liu et al., 2013; Verghese et al.,
2011), may be associated with more diffuse cognitive defi-
cits, depending on the nature and location of injury
(Greenwood, Lambert, et al., 2005).
Furthermore, if APOE-ε4 has a cognitive phenotype inde-
pendent of future AD diagnosis, APOE-ε2 genotype may also
be associated with its own cognitive phenotype, although the
supporting neurobiological mechanism is not clear. Amyloid
aggregation is an unlikely candidate, as the oldest-old ε2-
carriers have a similar presence of amyloid pathology
compared to ε4-carriers, despite reduced risk of dementia
(Berlau, Corrada, Head, & Kawas, 2009). Instead, APOE-ε2 may
promote synaptic integrity, suggested by greater dendritic
arborisation observed in APOE-ε2 transgenic mice, versus ε3
and ε4 (Dumanis et al., 2009), or facilitate anti-inflammatory
processes, as ApoE2 appears to be more effective at protect-
ing cells from oxidative stress-induced cell death compared to
ApoE3 and ApoE4 (Miyata & Smith, 1996; see Suri et al., 2013).
Although not the subject of this review, neuroimaging
provides system-level evidence for the neurobiological
mechanisms underpinning an APOE cognitive phenotype.
Altered brain structure and function in young ε4-carriers
supports APOE-related alteration in CNS function(s) prior to
the onset of AD pathology (e.g., Evans et al., 2017; Rusted et al.,
2013; Shine, Hodgetts, Postans, Lawrence, & Graham, 2015;
Suri et al., 2015). Neuroimaging findings may even inform
targets for investigation of APOE cognitive effects, e.g.,
cognitive processes associated with altered WM integrity
(Heise, Filippini, Ebmeier,&Mackay, 2011;Westlye et al., 2012,
c.f. Nyberg & Salami, 2014) or altered hippocampal connec-
tivity (Harrison, Burggren, Small, & Bookheimer, 2017; Heise
et al., 2014).
6.2. Recommendations for prodromal effect of APOE on
cognition
A growing body of work suggests that at least some cognitive
deficits in currently healthy older APOE-ε4 carriers are due to
prodromal AD. These findings do not rule out the possibility of
additional mechanisms of direct APOE influence on cognition,
and are important in demonstrating that cognitive deficits
relating to future diagnosis of AD can be detected early, in
adults currently considered to be healthy. APOE-ε4 genotype
alone provides limited prognostic information about whether
a person will be diagnosed with AD (Bookheimer & Burggren,
2009), so prodromal AD-related ε4 cognitive effects can be
utilised in future studies to develop preclinical cognitive bio-
markers to more precisely identify who is most at-risk. Sec-
ondary prevention clinical trials enriched with those most at-
c o r t e x 1 0 4 ( 2 0 1 8 ) 1 0 3e1 2 3 115risk of AD will reduce the sample size and longitudinal period
required to assess treatment efficacy (Holland, McEvoy,
Desikan, & Dale, 2012). Cognition can provide cheap, quick
and non-invasive preclinical biomarkers to be used alone, or
in combination with other biomarkers, such as CSF, PET or
MRI metrics, to identify those who will benefit most from
treatment and track early treatment efficacy.
Future studies aimed at utilising APOE genotype to char-
acterise the cognitive markers of prodromal AD pathology in
ε4-carriers require participants in whom prodromal AD is
likely to be present (i.e., over 60s), as well as longitudinal
designs to measure clinical outcomes, with sufficient follow-
up period to allow for conversion to AD. The cognitive do-
mains tested should be focused on those affected in early AD
to minimise multiple comparisons. Such studies may be
able to utilise existing data, for example through initiatives
such as the MRC Dementias Platform UK (DPUK; www.
dementiasplatform.uk), European Medical Information
Framework e Alzheimer's Disease (EMIF; http://www.emif.
eu/about/emif-ad) and Alzheimer's Disease Neuroimaging
Initiative (ADNI, http://adni.loni.usc.edu/), which pool data
from many existing ageing cohorts both locally and
internationally.7. Conclusions and future directions
APOE genotype is the strongest genetic risk factor for AD, yet
the influence of APOE on cognition in healthy adults remains
controversial. Some evidence suggests that at least some
APOE-ε4 cognitive deficits are due to early AD pathology,
whilst sensitive measures of cognition are beginning to reveal
subtle cognitive effects of APOE genotype in mid-adulthood,
prior to the onset of the AD prodromal period. To unpick
the direct and prodromal cognitive consequences of APOE
genotype, future studies need to address specific research
questions with methodology that is appropriate to the
neurobiological mechanism being investigated. Combining an
optimised cognitive approach with other biomarkers, e.g.,
neuroimaging, will provide additional evidence to make the
study of APOE and cognition useful for understanding cogni-
tive ageing and dementia.
Once we have a clearer understanding of the direct and
prodrome-mediated effect of APOE on cognition, further in-
vestigations of the cognitive consequences of interactions of
APOE genotype with other factors, e.g., cardiovascular health
(Caselli, Dueck, Locke, Sabbagh, et al., 2011; de Frias et al.,
2007; de Frias, Schaie, & Willis, 2014; Liu et al., 2010; McFall,
Sapkota, McDermott, & Dixon, 2016; West et al., 2008), hor-
mones (Burkhardt et al., 2004, 2006; Fiocco, Poirier, Joober, Nair,
& Lupien, 2008; Gerritsen, Comijs, Deeg, Penninx, & Geerlings,
2011; Panizzon et al., 2014), physical activity (e.g., Deeny et al.,
2008; Etnier et al., 2007) and gender (e.g., Lehmann et al.,
2006; Swan, Lessov-Schlaggar, Carmelli, Schellenberg, & La
Rue, 2005; Zokaei et al., 2017), as well as other genes, e.g.,
TOMM40 (Ferencz, Laukka, L€ovden, Kalpouzos, & Keller, 2013;
Schiepers et al., 2012), CHRNA4 (Espeseth et al., 2006;
Reinvang, Lundervold, Wehling, Rootwelt, & Espeseth, 2010),
BDNF (Sapkota et al., 2017; Tsai et al., 2008; Ward et al., 2014)
and COMT (Sapkota et al., 2017), is warranted. Increased use oftechnology, e.g., remote-monitoring devices, and big data
initiatives, such as UK Biobank (http://www.ukbiobank.ac.uk/),
will provide increasingly novel and rich information about the
effect of APOE on cognition.Conflicts of interest
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